You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Aptar posted 5% core sales growth, $217 million adjusted EBITDA at a 21.3% margin and $1.52 adjusted EPS. It deconsolidated Russian subsidiary effective September 21, 2026, recording a $61.2 million charge, and guides Q4 adjusted EPS to $1.39 to $1.47.
AptarGroup, Inc. reported third-quarter net sales of $1.02 billion, up 6%, and core sales growth of 5%, while operating margin fell to 13.3%. Net income attributable was $32.6 million after a $58.0 million loss on deconsolidating Russian operations on September 21, 2026.
AptarGroup reported third-quarter sales increased 6% to $1.02 billion and adjusted earnings per share of $1.52. A $58.0 million Russian subsidiary deconsolidation loss reduced reported earnings per share to $0.51.
OOO Aptar Vladimir, AptarGroup, Inc.’s Russian subsidiary, was placed under temporary external administration by a Russian presidential decree; as of December 31, 2025, it represented less than 0.6% of net sales and operating income and less than 1% of assets.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Third-quarter reported sales rose 6% and core sales rose 5%, but adjusted EPS fell 6% and adjusted EBITDA margin declined to 21.3%; full-year emergency-medicine sales are expected to decline approximately $65 million. Management guides to fourth-quarter adjusted EPS of $1.39-$1.47, while year-to-date free cash flow was $198 million, $272 million was returned to shareholders, and the quarterly dividend was increased.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA - Beauty non-GAAP | $44,742 | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA - Closures non-GAAP | $29,849 | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA - Pharma non-GAAP | $153,905 | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA for Reportable Segments non-GAAP | $228,496 | the three months ended June 30, 2026 filing | — |
| Core sales growth (Consumer Health Care) non-GAAP | 15% | the second quarter of 2026 filing | — |
| Core sales growth (Injectables) non-GAAP | 9% | the second quarter of 2026 filing | — |
| Corporate & Other costs | $15.9M | the quarter ended June 30, 2026 filing | — |
| Adjusted EBITDA margin non-GAAP | 20.7% | Q2 2026 | — |
| Adjusted EBITDA margins non-GAAP | 20% | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) non-GAAP | 21.7% | Six Months Ended June 30, 2026 | — |
| Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share non-GAAP | $2.61 | Six Months Ended June 30, 2026 | — |
| Core sales growth non-GAAP | 1% | Q2 2026 | — |
| Free Cash Flow non-GAAP | $99.22M | Six Months Ended June 30, 2026 | — |
| Share repurchases | $50M | Q2 2026 | — |
| Shares repurchased | 403K | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATR
this stock
Aptargroup, Inc.
|
$9.31B | +20.4% | +5.4% | 35.7 | 3.3% |
|
ISRG
Intuitive Surgical Inc
|
$167.12B | -14.9% | +20.5% | 58.4 | 2.1% |
|
BDX
Becton Dickinson & Co
|
$56.98B | — | +8.2% | 92.6 | 3.3% |
|
MDLN
Medline Inc.
|
$53.07B | -3.9% | +11.5% | — | 3.1% |
|
ALC
Alcon Inc
|
$37.37B | -1.9% | +10.5% | — | 4.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
AptarGroup, Inc. reported third-quarter net sales of $1.02 billion, up 6%, and core sales growth of 5%, while operating margin fell to 13.3%. Net income attributable was $32.6 million after a $58.0 million loss on deconsolidating Russian operations on September 21, 2026.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATR | +15.5% | +22.0% | +24.5% | +7.0% | +20.4% |
| SPY | -0.7% | -1.3% | +2.5% | +1.5% | +12.5% |
| vs SPY | +16.2% | +23.3% | +22.0% | +5.6% | +8.0% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
